ANIK — ANIKA THERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About ANIKA THERAPEUTICS INC (ANIK)
ANIKA THERAPEUTICS INC (ANIK) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $986,899. Across recent filings, tracked investors recorded 5 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in ANIK
How many top investors track ANIK
A small number of top investors own this.
ANIK Ownership Composition
How ANIKA THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Other74.5%
- Hedge Funds25.5%
Tracked investors reporting ANIK
- Ken GriffinMar 31, 2026Citadel AdvisorsShares68.1KValue$986.9K% Portfolio0.00%
- Steve CohenMar 31, 2026Point72 Asset ManagementShares29.2KValue$423.8K% Portfolio0.00%
- Izzy EnglanderDec 31, 2025Millennium ManagementShares26.2KValue$251.3K% Portfolio0.00%
Recent activity
- $251.3KFeb 17, 2026
- New$558.4KFeb 17, 2026
- New$986.9KMay 15, 2026
- New$423.8KMay 15, 2026
- New$182.2KNov 14, 2025
Frequently asked questions
- How many institutional investors hold ANIK?
- 3 tracked institutional investors disclosed a position in ANIK (ANIKA THERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of ANIK?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in ANIK, valued at $986,899.
- Did institutional ownership of ANIK increase or decrease?
- Across recent 13F filings, tracked investors recorded 5 new positions, 0 increased, 0 reduced, and 0 fully exited ANIK.
- Where does this ANIK ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.